These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 39173088)
1. Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Term Follow-Up of the Women's Health Initiative Randomized Trials. Chlebowski RT; Aragaki AK; Pan K; Haque R; Rohan TE; Song M; Wactawski-Wende J; Lane DS; Harris HR; Strickler H; Kauntiz AM; Runowicz CD J Clin Oncol; 2024 Oct; 42(30):3537-3549. PubMed ID: 39173088 [TBL] [Abstract][Full Text] [Related]
2. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. Chlebowski RT; Anderson GL; Aragaki AK; Manson JE; Stefanick ML; Pan K; Barrington W; Kuller LH; Simon MS; Lane D; Johnson KC; Rohan TE; Gass MLS; Cauley JA; Paskett ED; Sattari M; Prentice RL JAMA; 2020 Jul; 324(4):369-380. PubMed ID: 32721007 [TBL] [Abstract][Full Text] [Related]
3. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. Manson JE; Chlebowski RT; Stefanick ML; Aragaki AK; Rossouw JE; Prentice RL; Anderson G; Howard BV; Thomson CA; LaCroix AZ; Wactawski-Wende J; Jackson RD; Limacher M; Margolis KL; Wassertheil-Smoller S; Beresford SA; Cauley JA; Eaton CB; Gass M; Hsia J; Johnson KC; Kooperberg C; Kuller LH; Lewis CE; Liu S; Martin LW; Ockene JK; O'Sullivan MJ; Powell LH; Simon MS; Van Horn L; Vitolins MZ; Wallace RB JAMA; 2013 Oct; 310(13):1353-68. PubMed ID: 24084921 [TBL] [Abstract][Full Text] [Related]
4. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial. Chlebowski RT; Anderson GL; Sarto GE; Haque R; Runowicz CD; Aragaki AK; Thomson CA; Howard BV; Wactawski-Wende J; Chen C; Rohan TE; Simon MS; Reed SD; Manson JE J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26668177 [TBL] [Abstract][Full Text] [Related]
5. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. Shumaker SA; Legault C; Kuller L; Rapp SR; Thal L; Lane DS; Fillit H; Stefanick ML; Hendrix SL; Lewis CE; Masaki K; Coker LH; JAMA; 2004 Jun; 291(24):2947-58. PubMed ID: 15213206 [TBL] [Abstract][Full Text] [Related]
6. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. Manson JE; Aragaki AK; Rossouw JE; Anderson GL; Prentice RL; LaCroix AZ; Chlebowski RT; Howard BV; Thomson CA; Margolis KL; Lewis CE; Stefanick ML; Jackson RD; Johnson KC; Martin LW; Shumaker SA; Espeland MA; Wactawski-Wende J; JAMA; 2017 Sep; 318(10):927-938. PubMed ID: 28898378 [TBL] [Abstract][Full Text] [Related]
7. Effects of oral conjugated equine estrogens with or without medroxyprogesterone acetate on incident hypertension in the Women's Health Initiative hormone therapy trials. Swica Y; Warren MP; Manson JE; Aragaki AK; Bassuk SS; Shimbo D; Kaunitz A; Rossouw J; Stefanick ML; Womack CR Menopause; 2018 Jul; 25(7):753-761. PubMed ID: 29381666 [TBL] [Abstract][Full Text] [Related]
8. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. Heiss G; Wallace R; Anderson GL; Aragaki A; Beresford SA; Brzyski R; Chlebowski RT; Gass M; LaCroix A; Manson JE; Prentice RL; Rossouw J; Stefanick ML; JAMA; 2008 Mar; 299(9):1036-45. PubMed ID: 18319414 [TBL] [Abstract][Full Text] [Related]
9. Estrogen Plus Progestin and Colorectal Cancer: Long-Term Findings From the Women's Health Initiative Randomized Clinical Trial. Chlebowski RT; Aragaki AK; Pan K; Luo J; Rohan TE; Johnson KC; Wactawski-Wende J; Jung SY; Xiao Q; Lavasani S; Manson JE; Simon MS J Clin Oncol; 2024 Oct; 42(30):3530-3536. PubMed ID: 39028918 [No Abstract] [Full Text] [Related]
10. Effects of estrogen with and without progestin on urinary incontinence. Hendrix SL; Cochrane BB; Nygaard IE; Handa VL; Barnabei VM; Iglesia C; Aragaki A; Naughton MJ; Wallace RB; McNeeley SG JAMA; 2005 Feb; 293(8):935-48. PubMed ID: 15728164 [TBL] [Abstract][Full Text] [Related]
11. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Pickar JH; Yeh I; Wheeler JE; Cunnane MF; Speroff L Fertil Steril; 2001 Jul; 76(1):25-31. PubMed ID: 11438315 [TBL] [Abstract][Full Text] [Related]
12. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. Espeland MA; Rapp SR; Shumaker SA; Brunner R; Manson JE; Sherwin BB; Hsia J; Margolis KL; Hogan PE; Wallace R; Dailey M; Freeman R; Hays J; JAMA; 2004 Jun; 291(24):2959-68. PubMed ID: 15213207 [TBL] [Abstract][Full Text] [Related]
13. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials. Tang JY; Spaunhurst KM; Chlebowski RT; Wactawski-Wende J; Keiser E; Thomas F; Anderson ML; Zeitouni NC; Larson JC; Stefanick ML J Natl Cancer Inst; 2011 Oct; 103(19):1469-75. PubMed ID: 21878677 [TBL] [Abstract][Full Text] [Related]
14. Menopausal Hormone Therapy and Risks of First Hospitalized Heart Failure and its Subtypes During the Intervention and Extended Postintervention Follow-up of the Women's Health Initiative Randomized Trials. Liu L; Klein L; Eaton C; Panjrath G; Martin LW; Chae CU; Greenland P; Lloyd-Jones DM; Wactawski-Wende J; Manson JE J Card Fail; 2020 Jan; 26(1):2-12. PubMed ID: 31536806 [TBL] [Abstract][Full Text] [Related]
15. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. Pickar JH; Yeh IT; Wheeler JE; Cunnane MF; Speroff L Fertil Steril; 2003 Nov; 80(5):1234-40. PubMed ID: 14607581 [TBL] [Abstract][Full Text] [Related]
16. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. Anderson GL; Judd HL; Kaunitz AM; Barad DH; Beresford SA; Pettinger M; Liu J; McNeeley SG; Lopez AM; JAMA; 2003 Oct; 290(13):1739-48. PubMed ID: 14519708 [TBL] [Abstract][Full Text] [Related]
17. The effect of medroxyprogesterone acetate on estrogen-dependent risks and benefits--an attempt to interpret the Women's Health Initiative results. Kuhl H; Stevenson J Gynecol Endocrinol; 2006 Jun; 22(6):303-17. PubMed ID: 16785155 [TBL] [Abstract][Full Text] [Related]
18. The association of hormone therapy with blood pressure control in postmenopausal women with hypertension: a secondary analysis of the Women's Health Initiative clinical trials. Jiang X; Aragaki AK; Nudy M; Manson JE; Shadyab AH; Wild RA; Valdiviezo C; Gass M; Martin LW; Pan K; Stefanick ML; Robbins JA; Schnatz PF Menopause; 2023 Jan; 30(1):28-36. PubMed ID: 36256926 [TBL] [Abstract][Full Text] [Related]
19. Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials. Maalouf NM; Sato AH; Welch BJ; Howard BV; Cochrane BB; Sakhaee K; Robbins JA Arch Intern Med; 2010 Oct; 170(18):1678-85. PubMed ID: 20937929 [TBL] [Abstract][Full Text] [Related]
20. Women's Health Initiative clinical trials: potential interactive effect of calcium and vitamin D supplementation with hormonal therapy on cardiovascular disease. Jiang X; Nudy M; Aragaki AK; Robbins JA; Manson JE; Stefanick ML; OʼSullivan DM; Shikany JM; LeBlanc ES; Kelsey AM; Cauley J; Martin LW; Payne ME; Johnson KC; Howard B; Schnatz PF Menopause; 2019 Aug; 26(8):841-849. PubMed ID: 31145202 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]